Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(33%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_4
1
17%
Ph not_applicable
5
83%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
5(83.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(3)
Other(1)

Detailed Status

Completed3
Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (16.7%)
N/A5 (83.3%)

Trials by Status

recruiting233%
completed350%
unknown117%

Recent Activity

2 active trials
Showing 5 of 6
recruitingnot_applicable

Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia

NCT06183307
recruitingnot_applicable

Effects of Nattokinase on Cardiovascular Risk, Gut Microbiota, Sleep, and Cognition in Metabolic Syndrome With Sleep Disorders.

NCT07229521
completednot_applicable

Nattokinase Atherothrombotic Prevention Study

NCT02080520
unknownnot_applicable

Improving Cerebral Blood Flow and Cognitive Function in Patients With Asymptomatic Intracranial / Carotid Stenosis With Nattokinase (ICC-PACS)

NCT05200234
completedphase_4

Nattokinase Supplementation and Hemostatic Factors

NCT02913170
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06183307Not Applicable

Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia

Recruiting
NCT07229521Not Applicable

Effects of Nattokinase on Cardiovascular Risk, Gut Microbiota, Sleep, and Cognition in Metabolic Syndrome With Sleep Disorders.

Recruiting
NCT02080520Not Applicable

Nattokinase Atherothrombotic Prevention Study

Completed
NCT05200234Not Applicable

Improving Cerebral Blood Flow and Cognitive Function in Patients With Asymptomatic Intracranial / Carotid Stenosis With Nattokinase (ICC-PACS)

Unknown
NCT02913170Phase 4

Nattokinase Supplementation and Hemostatic Factors

Completed
NCT00749801Not Applicable

Efficacy and Safety of Geneferm Nattokinase

Completed

All 6 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
6